Neuphoria Therapeutics (NEUP) Long-Term Deferred Tax (2023 - 2025)
Neuphoria Therapeutics (NEUP) posted quarterly Long-Term Deferred Tax of $26.1 million for Q2 2025, down 5.78% year-over-year from $27.7 million in Q2 2024, and down 5.78% quarter-over-quarter from $27.7 million in Q2 2024.
Neuphoria Therapeutics (NEUP) Long-Term Deferred Tax (2023 - 2025) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Long-Term Deferred Tax for 3 consecutive years, with $26.1 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Long-Term Deferred Tax fell 5.78% year-over-year to $26.1 million; the TTM figure through Jun 2025 stood at $26.1 million (down 5.78% YoY), while the FY2025 annual figure was $26.1 million, down 5.78% from the prior year.
- Long-Term Deferred Tax retreated to $26.1 million in Q2 2025 per NEUP's latest filing, from $27.7 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $27.7 million in Q2 2024 and bottomed at $23.5 million in Q2 2023.
- Historically, Long-Term Deferred Tax has averaged $25.8 million across 3 years, with a median of $26.1 million in 2025.
- Annual changes were most pronounced in 2024 — Long-Term Deferred Tax climbed 17.87% — and 2025, when it fell 5.78%.
- Neuphoria Therapeutics' Long-Term Deferred Tax stood at $23.5 million in 2023, then gained by 17.87% to $27.7 million in 2024, then decreased by 5.78% to $26.1 million in 2025.
- Business Quant data shows NEUP's Long-Term Deferred Tax at $26.1 million in Q2 2025, $27.7 million in Q2 2024, and $23.5 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 26.10 Mn |
| Jun 30, 2024 | 27.70 Mn |
| Jun 30, 2023 | 23.50 Mn |